Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Refractory Pediatric Solid and CNS Tumors

NCT07793994 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT07793994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07793994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Refractory Pediatric Solid and CNS Tumors
Lead sponsor
Dana-Farber Cancer Institute
Phase
Not applicable
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
March 31, 2030
Enrollment
130 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cns tumor, pediatric cancer, refractory cancer, relapsed cancer, solid tumor